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The scientific advances made in the year leading up to the 15th Conference on 
Retroviruses and Opportunistic Infections were overshadowed, to some extent, 
by setbacks in the AIDS vaccine research arena and in particular, the failure of 
the Merck STEP trial. Arguably, these disappointments were offset by strong 
advances that were being made in basic science and pathogenesis. In particular, 
recent discoveries into cellular factors that influence virus–host cell interplay 
and new insights into the mechanisms of viral pathogenesis were highlighted 
at the meeting. These research discoveries paint an optimistic picture regarding 
the development of new strategies to combat HIV and AIDS.
Cellular	Restrictions	and	
Viral	Defenses
One of the most exciting areas of AIDS 
research in the past several years has 
been in cellular restrictions. This area 
of research was initiated with indepen-
dent demonstrations by Malim’s and 
Kabat’s groups1,2 that cells retained an 
activity that dominantly suppressed 
HIV-1 infection and that the HIV-1 ac-
cessory protein Vif counteracted the 
dominant restriction. Four years later, 
Malim and colleagues identified the 
nature of the restriction itself.3 The re-
striction, called APOBEC 3G, is a cyti-
dine deaminase that, when packaged 
into virions, causes extensive G-to-A 
hypermutation during reverse tran-
scription of viral complementary DNA 
(cDNA). This compromises the stability 
of the viral cDNA as well as the func-
tionality of the resulting provirus. To 
avoid this cellular restriction, primate 
lentiviruses have evolved a vif	 gene 
whose function is to target APOBEC 3 
proteins for proteasomal destruction. 
In 2004 the Sodroski laboratory 
identified a second cellular restriction 
termed TRIM 5a.4 This protein targets 
the viral Gag polyprotein to exert a spe-
cies-specific inhibitory effect on early 
events in virus infection. For example, 
the targeting of HIV-1 Gag by monkey 
TRIM 5a explains the resistance of cer-
tain monkey cells to HIV-1 infection. 
Subtle amino acid changes can render 
Gag insensitive to TRIM 5a restriction. 
Presentations by Guatelli (Abstract 
104A) and Bieniasz (Abstract 114) de-
scribed a third antiviral restriction that 
is counteracted by the accessory pro-
tein Vpu of primate lentiviruses. Re-
search from a number of groups has 
revealed that in primary cells and in 
some cell lines, Vpu-defective viruses 
are unable to detach from the surface 
of the infected cell. Spearman’s group5 
provided evidence that these cells con-
tain a dominant restriction and that the 
Vpu protein counteracts the restriction. 
At the conference, the Bieniasz and 
Guatelli groups independently revealed 
the nature of the cellular restriction that 
is counteracted by Vpu. In his plenary 
presentation, Bieniasz summarized 
recently published findings6 that Vpu 
counters a cellular protein called CD317, 
or BST-2. Bieniasz’s group has coined 
this protein a tetherin because it teth-
ers fully formed virions to the surface 
of the infected cell. Their research has 
revealed that tetherin is an interferon-
a inducible protein that causes reten-
tion of viral particles on the cell surface. 
These viral particles are subsequently 
endocytosed into CD317-positive cyto-
plasmic compartments. When tetherin 
was depleted by RNA interference, vi-
rus particle release was no longer Vpu-
dependent. Bieniasz also demonstrated 
that Vpu colocalized with tetherin in 
infected cells. Guatelli, in his presenta-
tion, extended these findings and dem-
onstrated that Vpu directly interacts 
with BST-2 and in the presence of Vpu, 
surface levels of BST-2 are diminished. 
The BST-2 protein is a glycosylphospha-
tidylinositol (GPI)-anchored membrane 
protein of unknown function; BST-2 
most likely, crosslinks cholesterol-rich 
virion membranes with the plasma 
membrane of the cell. Furthermore, the 
cellular expression of BST-2 appears to 
mimic the cells in which virus release 
is Vpu-dependent. Therefore, BST-2 ex-
pression is high in HeLa cells, in which 
virus production is Vpu-dependent, but 
low in HEK293 cells, in which Vpu is 
not required for efficient virus release. 
These presentations summarize excit-
ing advances in understanding cellular 
restrictions against primate lentiviruses. 
That 2 of the 4 viral accessory proteins 
(Vif, Vpu) have evolved as counterde-
fenses to cellular restrictions illustrates 
how primate lentiviruses have respond-
ed to evolutionary pressure to evolve 
defense mechanisms to counter these 
cellular restrictions. Small-molecule 
inhibitors of these viral accessory pro-
teins would be predicted to block the 
viral defense against the cellular restric-
tions, thereby rendering cells resistant 
to virus infection. 
Cellular	Cofactors	in	the	Viral	
Replication	Cycle
Presentations describing new cellular 
cofactors of HIV-1 replication were also 
highlights of the conference. Primate 
lentiviruses have a limited genetic rep-
ertoire comprising only 9 genes. There-
fore, primate lentiviruses commandeer 
cellular proteins to complete certain 
aspects of their replication cycle. For 
example, these viruses use cell-sur-
face proteins such as CD4, CCR5, and 
CXCR4 to gain entry to the host cell. An 
exciting presentation by Brass (Abstract 
104bLB) summarized his group’s re-
cent published study,7 which identified 
numerous host proteins required for 
HIV-1 infection. Brass and colleagues 
employed a functional genomic screen 
to survey proteins of the cell that were 
necessary for early and late events in 
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HIV-1 replication. In their screen, they 
transfected HIV-1-susceptible indicator 
cells with short interfering RNA (siRNA) 
pools. These cells were then infected 
with HIV-1. Supernatants of the trans-
fected cells were recovered and used 
to initiate fresh infections of indicator 
cells. This 2-step process was used to 
reveal genes that were important for 
early events in viral replication as well 
as late events in the viral life cycle. 
The approach identified over 250 
host factors (referred to by the group 
as HIV-dependency factors, HDFs). 
Thirty-six host factors identified in 
the screen were previously implicated 
in HIV-1 biology (genes such as CD4,	
CXCR4,	 nuclear	 factor	 [NF]-kB). The 
remaining 237 genes were novel, 
and more than 100 of these revealed 
a phenotype when silenced by 2 or 
more individual siRNAs. The valid-
ity of the observations was increased 
by the fact that some HDFs found to 
be important for HIV replication were 
part of the same macromolecular com-
plex. For example, 4 of 6 subunits of 
the nuclear pore complex nup160 sub-
complex were identified as HDFs. The 
involvement of the nuclear pore com-
plex in HIV-1 infection is not surprising 
because a long-recognized feature of 
primate lentivirus infection is the abil-
ity to translocate through the nuclear 
pore envelope. This is a property that 
has been considered necessary for the 
ability of primate lentiviruses to infect 
nondividing cells. Therefore, silencing 
of nuclear pore complex components 
likely prevented efficient translocation 
of viral reverse transcription complex-
es from the cytoplasm to the nucleus. 
Three late-acting HDFs were found 
to encode enzymes involved in the gly-
cosylation of cellular proteins. Again, 
this is not surprising because the viral 
envelope protein is heavily glycosylat-
ed, and this modification is necessary 
for envelope function. However, the 
screen by Brass and colleagues revealed 
some unexpected HDFs. For example, 
several factors involved in autophagy, 
which is essential for the degradation 
and recycling of cellular components, 
were required for HIV-1 infection. This 
finding is surprising because no pub-
lished scientific data link the HIV-1 rep-
lication cycle with autophagy. Similarly, 
RAB6 and VPS53, which are important 
for retrograde vesicular transport, were 
necessary for HIV-1 infection but were 
dispensable for murine leukemia virus 
(MLV) infection and for HIV-1 infection 
by the endocytic route. 
Further insight into fundamental 
steps in HIV-1 replication were also re-
vealed by the demonstration by Brass 
and colleagues that the karyphenin 
transportin3 and RAN BP2 were re-
quired for HIV-1 infection. The RAN 
BP2 protein is large and lies on the cy-
toplasmic side of the nuclear pore. This 
protein contains phenylalanine-glycine 
(FG)-domains. Current models of nucle-
ar import suggest that nuclear pore fila-
ments capture proteins to be imported, 
and these proteins “slide” down the FG 
domains toward the nuclear pore itself. 
Nuclear pore proteins also contain FG 
domains, which then capture the im-
porting cargo. Transportin is a nuclear 
importer shown to be important for re-
cruiting serine arginine splice factors to 
the nucleus. It was required for HIV-1 en-
try and for HIV-1 entry by the endocytic 
route but was dispensable for MLV infec-
tion. This information fits current mod-
els of lentivirus biology, in which lenti-
viruses have the capacity to translocate 
across the nuclear envelope, whereas 
simple retroviruses such as MLV cannot. 
These observations underscore a 
model in which HIV-1 usurps transpor-
tin3 and proteins of the nuclear pore 
complex to shuttle into the nucleus of 
the nondividing cell. Future research 
will seek to determine which HIV-1 
proteins interact with these nuclear 
pore constituents. More importantly, 
the identification of more than 200 
novel cellular cofactors is an impor-
tant advancement because each cel-
lular cofactor represents a potential 
point of intersection with which to 
truncate HIV-1 replication. For exam-
ple, small-molecule inhibitors of HIV-1 
envelope–CCR5 interaction are being 
exploited clinically for the treatment 
of HIV-1 infection. The challenge will 
be to use this information to acceler-
ate the development of novel HIV-1 
inhibitors.
In session 31, several presentations 
focused on cellular proteins that influ-
ence HIV–host cell interactions. For ex-
ample, Hakata (Abstract 100) described 
the role of the cellular proteins DCAF1 
and DDB1 in the activity of the HIV-1 
accessory protein Vpr. Several activi-
ties have been described for the HIV-1 
Vpr protein, including enhancement 
of macrophage infection, cell cycle ar-
rest, and association with DNA repair 
enzymes. Hakata presented evidence 
that the interaction of Vpr with pro-
teins such as DDB1 is species-specific 
in that the Vpr of simian immunodefi-
ciency virus of African green monkeys 
(SIVagm) was unable to bind human 
DDB1. As a consequence, Vpr of SIVagm 
was unable to induce cell-cycle arrest 
in human cells. This underscores many 
recent studies implicating DDB1 as a 
cellular cofactor necessary for induc-
tion of cell-cycle arrest by Vpr. 
In another presentation (Abstract 
150), de Noronha described the iden-
tification of proteins that interact with 
HIV-1 Vpr to mediate its ability to induce 
cell-cycle arrest. His group’s studies also 
revealed an association between HIV-
1 Vpr and a previously described Vpr 
binding protein (originally Vpr BP, now 
called DCAF1) that forms part of a ubiq-
uitin-ligase complex. This suggests that 
Vpr commandeers the ubiquitin-ligase 
complex perhaps to degrade other cel-
lular proteins; however, the identities of 
cellular proteins that may be targeted 
for degradation by Vpr are not known. 
The ability of Vpr to induce cell-cycle ar-
rest was inhibited when DDB1 was de-
pleted, suggesting that the protein tar-
geted for degradation by Vpr is required 
for normal cell-cycle progression. 
The presenter also raised the pos-
sibility that Vpr may target DNA repair 
enzymes for degradation. Previous 
studies have suggested that Vpr asso-
ciates with and promotes degradation 
of the DNA repair enzyme uracil DNA 
glycosylase to prevent destruction of 
APOBEC-3-edited cDNA. He presented 
evidence that overexpression of DDB1, 
a protein that binds Vpr, impaired turn-
over of uracil DNA glycosylase and pro-
moted its redistribution to the cell nu-
cleus. With his colleagues, de Noronha 
suggests a model in which uracil DNA 
glycosylase associates normally with 
the DCAF1, DDB1, CUL4A ubiquitin-li-
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gase complex and is targeted for prote-
asomal destruction upon ubiquitylation 
by this complex. In the presence of Vpr, 
however, association of uracil DNA gly-
cosylase with the ubiquitin-ligase com-
plex is enhanced, thereby augmenting 
degradation or nuclear shuttling of the 
glycosylase. 
Viral	Navigation	Through		
the	Cell
New insight was provided in session 
15 into how HIV-1 navigates through 
the cell and between cells. After in-
fection of cells by HIV-1, reverse tran-
scription of viral cDNA is initiated in 
the cytoplasm. Nascent viral cDNA 
then translocates to the nucleus in the 
context of a high-molecular-weight 
nucleoprotein complex (commonly 
referred to as the reverse transcription 
complex). In the nucleus, a derivative 
of the reverse transcription complex 
(commonly referred to as the preinte-
gration complex) binds to chromatin 
and catalyzes integration of viral cDNA 
with host cell DNA. 
The diameter of the reverse tran-
scription complex has been estimated 
to be approximately 30 nm, whereas 
the diameter of the cell is nearer 20 
μm to 30 μm. Therefore, the voyage 
that the viral reverse transcription 
complex takes from the point of virus 
entry at the cell membrane to the host 
cell nucleus can be compared to the 
movement of a soccer ball across a 
soccer field. Thus,  the virus likely uses 
a road map to navigate through the cell 
in an orderly fashion. 
In her presentation (Abstract 49), 
Arhel provided a summary of current 
knowledge about the road map used by 
viruses such as HIV-1 to navigate from 
the plasma membrane to the nuclear 
envelope. She presented a model in 
which reverse transcription complexes 
deposited in the cytoplasm upon in-
fection of the cell rapidly contact mi-
crotubules and then transit to actin 
filaments. These reverse transcription 
complexes then move along actin fila-
ments at a speed of approximately 1 
μm/s toward the nuclear membrane. 
At the nuclear membrane, a moiety on 
viral cDNA, referred to as the central 
DNA flap, promotes the maturation 
of reverse transcription complexes 
to the preintegration complexes by 
prompting dissociation of the capsid 
shell. These events are prerequisites 
for the ability of the reverse transcrip-
tion complex to translocate through 
the nuclear pore complex. Arhel and 
colleague Chameau have used electron 
microscopy to provide images of re-
verse transcription complexes docked 
at a nuclear pore complex. 
Viral	Dissemination	
Between	Cells
Hope, in his introductory comments 
to the session, summarized current 
models of how HIV-1 virions are trans-
mitted between cells. Previously, it 
was assumed that in HIV-1-infected 
individuals, viral particles produced 
by infected cells entered body fluids, 
where they randomly encountered 
new target cells. However, studies 
from the research groups of Martin 
and Ho demonstrated that cell-free 
simian immunodeficiency virus (SIV) 
particles, when injected into monkeys, 
were rapidly cleared from body fluids 
to the extent that cell-free virions had 
a half-life of minutes. For this reason, 
many investigators have favored the 
model in which viruses spread in the 
tissues between cells that are in close 
contact. Hope presented microscopic 
evidence for the transmission of vi-
ruses between cells through a virologic 
or infectious synapse.8 These synapses 
comprise existing cellular pathways 
involved in antigen presentation and 
T-cell communication (for review see 
Jolly and Sattentau9). 
It is now apparent that a variety of 
retroviruses and lentiviruses exploit re-
ceptor-containing adhesive junctions 
formed between cells in order to pass 
directly from infected to uninfected 
immune cells. Mothes (Abstract 50) 
presented live images of retroviruses 
transmitting between cells and sum-
marized exciting new published in-
formation on the role of nanotubes 
in the transmission of HIV-1 between 
cells.10 He and his group have been in-
vestigating why the infectivity of HIV-1 
is 2 to 3 log10 higher when cells are in 
contact and whether movement be-
tween cells is through diffusion or a di-
rect process. For example, in the case 
of  human T-lymphotrophic virus 1, 
there is an almost complete lack of vi-
rus-particle release into cultured fluids, 
yet the virus is able to spread efficient-
ly between cells. Using fluid fluores-
cently labeled MLV as a model system, 
Mothes and colleagues obtained evi-
dence that viruses move from infected 
to uninfected cells through filopodia. 
These filopodia are thin membrane 
projections along which viral particles 
“surf” unidirectionally toward the un-
infected cell. Filopodia are normally 
short-lived structures; however, during 
the transmission of viral particles, they 
appear to form stable bridges between 
infected and uninfected cells. Virus 
particles can take in the order of 20 
minutes to move along filopodia that 
connect the infected and uninfected 
cells. These filopodia can extend 10 
μm to 20 μm from the surface of the 
infected cell. 
The presence of filopodial bridges 
between infected and uninfected cells 
is dependent upon the presence of the 
viral envelope in the infected cell and 
the transmembrane receptor on the 
target cell. Although filopodia appear 
as rodlike membrane protrusions, vi-
rus particles surf on the outside of the 
filopodia during cell-to-cell transmis-
sion. The HIV-1 transmits across filo-
podia formed between T cells.10 Also, 
nanotubes physically connect T cells 
over long distances and offer a route 
of transmission for HIV-1. Nanotubes 
have been shown to connect many cell 
types and allow transmission of cal-
cium signals. They are formed when T 
cells make contact and subsequently 
part, and they can extend several cell 
diameters (100 μm). As with the distri-
bution of MLV through filopodia, HIV 
dissemination through nanotubes is re-
ceptor dependent and occurs at a rate 
of approximately 0.08 μm/s. There-
fore, membrane nanotubes provide a 
novel route for cell-to-cell dissemina-
tion of HIV-1. Nanotubes most likely 
avoid the rate-limiting diffusion step 
of cell-free virus spread, and further, 
may help minimize exposure of the 
virus particle to neutralizing antibody. 
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Inhibitors	and	Enhancers	of	Viral	
Infectivity
Kirchhoff, in his plenary presentation 
(Abstract 66), described the presence 
of natural enhancers and inhibitors of 
HIV-1 infectivity. He and his colleagues 
undertook a systematic analysis of 
compounds present in human body 
fluids that could influence HIV-1 in-
fectivity. The investigators obtained a 
peptide library from large volumes of 
hemofiltrate obtained from individuals 
with renal failure. This hemofiltrate con-
tains toxins as well as substances with 
a molecular rate less than 30 kDa. The 
peptide library obtained from the he-
mofiltrate was then screened for anti-
HIV-1 infectivity. 
A 20-amino-acid fragment of a1-anti-
trypsin, termed VIRIP, was identified as 
a potent inhibitor of HIV-1 replication. 
The protein a1-antitrypsin is present 
in large quantities in individuals with 
infection and inflammation. Its main 
function is to inhibit neutrophil elastase 
in the lung and the liver. The peptide 
VIRIP was active against all HIV-1 and 
SIV isolates and inhibited viral entry.11 
Although the inhibitory concentration 
of the initial VIRIP was in the micromo-
lar range, structure-activity-relationship 
analysis led to the development of ana-
logues with greatly increased antiviral 
potency. Importantly, VIRIP was active 
against HIV-1 variants resistant to other 
types of entry inhibitors such as T20. 
These studies suggest that VIRIP may 
target a novel step in HIV-1 entry be-
fore or shortly after insertion of the fu-
sion peptide of HIV-1 envelope into the 
target cell membrane. 
Kirchhoff and colleagues then used 
a similar approach to screen a semen-
derived peptide library for novel in-
hibitors of HIV-1 infection. Although 
the goal was to identify an inhibitor 
of HIV-1 infection in semen, all of the 
peptide pools analyzed failed to sig-
nificantly inhibit HIV-1 infection. In 
contrast, 1 of the peptide fractions 
markedly enhanced HIV-1 infection. 
This fraction contained a 34- to 40-
amino-acid fragment of prostatic acid 
phosphatase (PAP). Although freshly 
diluted synthetic PAP fragments were 
inactive against HIV-1 infection, these 
became active after overnight incuba-
tion. Electron microscopy of the active 
form revealed the presence of amyloid 
fibrils of PAP. These fibrils were coined 
semen enhancer of virus infection 
(SEVI) and were found to capture vi-
rus particles and mediate their attach-
ment to the surface of target cells. The 
SEVI enhanced both R5 and X4 HIV-1 
infection of lymphocytes and macro-
phages. The enhancing effect of SEVI 
was greatly manifested during infec-
tion with low amounts of input virus. 
Remarkably, SEVI enhanced HIV-1 in-
fection of lymphocytes and cells of the 
CEM cell line by up to 400,000-fold. 
This meant that in the presence of 
SEVI, 1 to 3 HIV-1 particles was suf-
ficient for productive infection.12 This 
study has important implications for 
the understanding of HIV-1 transmis-
sion at mucosal surfaces and for the 
development of microbicide. It will 
be important to identify the protease 
that clears PAP to generate the active 
peptide because interfering with pep-
tide formation as well as amyloid fibril 
formation could represent a strategy 
for prevention of HIV-1 transmission 
across mucosal surfaces.
Underlying	Mechanisms	of	Viral	
Pathogenicity
Exciting research aimed at understand-
ing the underlying mechanism of patho-
genic lentiviral infections was represent-
ed at the meeting in sessions 11 and 
36. Pathogenic lentivirus infection (eg, 
HIV-1 infection of humans, SIV infec-
tion of rhesus macaques) is reflected by 
high-level viremia, accelerated CD4+ 
lymphocyte turnover, and increased im-
mune activation. In contrast, nonpatho-
genic lentivirus infections (eg, SIV infec-
tion of sooty mangabeys) is reflected 
by high-level viremia and accelerated 
CD4+ lymphocyte turnover but normal 
levels of immune activation. Therefore, 
the extent of immune activation ap-
pears to be a distinguishing feature be-
tween pathogenic and nonpathogenic 
lentivirus infection.
For this reason, mechanisms driv-
ing immune activation have been of 
intense interest to AIDS investigators 
because this area may hold the key 
to how HIV-1 causes disease. At this 
year’s conference, research was pre-
sented to suggest that immune activa-
tion is driven by translocation of bacte-
rial products across mucosal surfaces. 
At last year’s conference (2007), sever-
al presentations revealed the rapid de-
struction of gut lymphoid tissue during 
acute HIV-1 infection. Those studies 
showed that CD4+, CCR5+ memory 
T cells were rapidly depleted as a con-
sequence of HIV-1 infection.
This year, 4 presentations (Abstracts 
115, 116, 117LB, 374) provided evidence 
that a subset of these cells (TH17-CD4+ 
T cells) are preferentially depleted in 
the gastrointestinal (GI) tract of HIV-1–
infected humans but not SIV-infected 
sooty mangabeys. The significance of 
this finding is that TH17 cells produce 
interleukin 17 (IL-17), which is thought 
to be important for antibacterial im-
munity. This cytokine is responsible 
for recruiting neutrophils, inducing the 
proliferation of GI enterocytes, and in-
ducing the production of antibacterial 
defensins. The TH17 cells were found to 
be preferentially located in the GI tract 
but present at very low frequencies in 
blood. Therefore, the destruction of 
TH17 cells may undermine the ability 
of the immune system to control micro-
bial agents. Furthermore, if IL-17 plays 
an important role in the proliferation of 
GI enterocytes, loss of the TH17-CD4+ 
subset may compromise the integrity 
of mucosal surfaces and permit trans-
location of bacterial products from the 
gut lumen into mucosal tissue. 
This hypothesis was supported by 
2 presentations (Abstracts 119, 377) 
that demonstrated a direct correlation 
between the extent of immune acti-
vation and the presence of bacterial 
products such as lipopolysaccharide 
or bacterial DNA. Because activated 
lymphocytes are preferred targets for 
HIV-1 infection, the increased immune 
activation driven by microbial translo-
cation would serve to enhance condi-
tions for viral replication and spread. 
These observations have very im-
portant implications for HIV-1 patho-
genesis and the treatment of HIV-1 
infection. If damage to the mucosal 
barrier and microbial translocation 
are triggering events in pathogenic in-
International AIDS Society–USA        Topics in HIV Medicine
5
fection, strategies aimed at preserving 
mucosal activity and neutralizing mi-
crobial products would be predicted to 
limit the extent of pathogenicity. Next 
year’s conference is likely to provide a 
forum for the presentation of research 
findings based on these therapeutic 
strategies.
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